Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion [Seeking Alpha]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Seeking Alpha
Investing Group Leader Follow Play 19min Summary Relay Therapeutics, Inc. reported positive interim data from its phase 1 ReDiscover study, using RLY-2608 + fulvestrant for treatment of PI3Ka-mutated HR+/HER2- locally advanced or metastatic breast cancer patients. Key upcoming milestones for RLY-2608 program includes presenting data at the San Antonio Breast Cancer Symposium in December 2024 and initiating a phase 3 study in 2025. Expansion opportunities of the RLY-2608 program includes two triplet regimens targeting 1st-line PI3Ka-mutant HR+/HER2- breast cancer patients and phase 1 study for tumors with vascular formations starting in Q1 2025. The global breast cancer drugs market size is projected to surpass $78.61 billion by 2033. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Jacob Wackerhausen/iStock via Getty Images Relay Therapeutics, Inc. NASDAQ: RLA
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at HC Wainwright from $19.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Relay Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate HighlightsGlobeNewswire
- Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024GlobeNewswire
RLAY
Earnings
- 11/6/24 - Beat
RLAY
Sec Filings
- 11/6/24 - Form 10-Q
- 11/6/24 - Form 8-K
- 10/30/24 - Form 4
- RLAY's page on the SEC website